Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2022-04-13 00:00:00 ET · period of report 2022-04-11 · accession 0001437749-22-008915 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-04-13 | 2022-04-11+ | BLFS | Rice Michael | CEO, Dir | S - Sale+OE | $19.30 | -20.0K | 327.2K | -6% | -$386.1K |
| DM | 2022-04-13 | 2022-04-11+ | BLFS | Rice Michael | CEO, Dir | M - OptEx | $1.90 | +77.7K | 394.9K | +25% | +$147.7K |
| DM | 2022-04-13 | 2022-04-11+ | BLFS | Rice Michael | CEO, Dir | M - OptEx | $0.00 | -77.7K | 70.0K | -53% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-13 | S | D | 10,000 | $19.06 | 384,891 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.61 to $19.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2022-04-12 | M | A | 57,736 | — | 384,891 | D | — | — | (F3) The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| 3 | Common | Common Stock | 2022-04-11 | S | D | 10,000 | $19.55 | 327,155 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.13 to $19.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2022-04-11 | M | A | 10,000 | $1.90 | 337,155 | D | — | — | |
| 5 | Common | Common Stock | 2022-04-13 | M | A | 10,000 | $1.90 | 394,891 | D | — | — | |
| 6 | Derivative | Restricted Stock Award | 2022-04-12 | M | D | 57,736 | $0.00 | 0 | D | $0.00 · — to — | 57,736 Common Stock | (F3) The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| 7 | Derivative | Employee Stock Option | 2022-04-13 | M | D | 10,000 | $0.00 | 60,000 | D | $1.90 · — to 2026-03-15 | 10,000 Common Stock | (F5) On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. |
| 8 | Derivative | Employee Stock Option | 2022-04-11 | M | D | 10,000 | $0.00 | 70,000 | D | $1.90 · — to 2026-03-15 | 10,000 Common Stock | (F5) On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. |